Literature DB >> 19359216

The CD300 family of molecules are evolutionarily significant regulators of leukocyte functions.

Georgina J Clark1, Xinsheng Ju, Courtney Tate, Derek N J Hart.   

Abstract

The CD300 glycoproteins are a family of cell surface molecules that modulate a diverse array of cell processes via their paired triggering and inhibitory receptor functions. Family members share a common evolutionary pathway and at least one member of the family has undergone significant positive selection, indicating their crucial value to the host. This review clarifies the occasionally confusing usage of nomenclature for the CD300 family and summarizes our current understanding of their genomics, expression and function. Their ability to fine tune leukocyte function and immune responses highlights several potential options to exploit the CD300 molecules as therapeutic targets in chronic inflammatory diseases, allergy and other disease states.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19359216     DOI: 10.1016/j.it.2009.02.003

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  52 in total

Review 1.  Triggering receptor expressed on myeloid cells receptor family modulators: a patent review.

Authors:  Christopher J Pelham; Amit N Pandya; Devendra K Agrawal
Journal:  Expert Opin Ther Pat       Date:  2014-11-01       Impact factor: 6.674

2.  Human CD300a binds to phosphatidylethanolamine and phosphatidylserine, and modulates the phagocytosis of dead cells.

Authors:  Venkateswara R Simhadri; John F Andersen; Eric Calvo; Seung-Chul Choi; John E Coligan; Francisco Borrego
Journal:  Blood       Date:  2012-02-01       Impact factor: 22.113

Review 3.  The innate immune system in transplantation.

Authors:  Martin H Oberbarnscheidt; Daniel Zecher; Fadi G Lakkis
Journal:  Semin Immunol       Date:  2011-07-01       Impact factor: 11.130

Review 4.  The CD300 molecules: an emerging family of regulators of the immune system.

Authors:  Francisco Borrego
Journal:  Blood       Date:  2013-01-04       Impact factor: 22.113

5.  An immunoglobulin-like receptor, Allergin-1, inhibits immunoglobulin E-mediated immediate hypersensitivity reactions.

Authors:  Kaori Hitomi; Satoko Tahara-Hanaoka; Satoru Someya; Akira Fujiki; Hideaki Tada; Tetsuya Sugiyama; Shiro Shibayama; Kazuko Shibuya; Akira Shibuya
Journal:  Nat Immunol       Date:  2010-06-06       Impact factor: 25.606

6.  Genomic and functional characterization of the diverse immunoglobulin domain-containing protein (DICP) family.

Authors:  Robert N Haire; John P Cannon; Marci L O'Driscoll; David A Ostrov; M Gail Mueller; Poem M Turner; Ronda T Litman; Gary W Litman; Jeffrey A Yoder
Journal:  Genomics       Date:  2012-02-21       Impact factor: 5.736

7.  CD300a is expressed on human B cells, modulates BCR-mediated signaling, and its expression is down-regulated in HIV infection.

Authors:  Rodolfo Silva; Susan Moir; Lela Kardava; Karen Debell; Venkateswara R Simhadri; Sara Ferrando-Martínez; Manuel Leal; José Peña; John E Coligan; Francisco Borrego
Journal:  Blood       Date:  2011-04-11       Impact factor: 22.113

8.  Reuse of public, genome-wide, murine eosinophil expression data for hypotheses development.

Authors:  Jillian O Grace; Astha Malik; Hadar Reichman; Ariel Munitz; Artem Barski; Patricia C Fulkerson
Journal:  J Leukoc Biol       Date:  2018-05-14       Impact factor: 4.962

9.  Human Th1 cells that express CD300a are polyfunctional and after stimulation up-regulate the T-box transcription factor eomesodermin.

Authors:  Sriram Narayanan; Rodolfo Silva; Giovanna Peruzzi; Yelina Alvarez; Venkateswara R Simhadri; Karen Debell; John E Coligan; Francisco Borrego
Journal:  PLoS One       Date:  2010-05-13       Impact factor: 3.240

10.  Negative regulation of autoimmune demyelination by the inhibitory receptor CLM-1.

Authors:  Hongkang Xi; Kenneth J Katschke; Karim Y Helmy; Paige A Wark; Noelyn Kljavin; Hilary Clark; Jeffrey Eastham-Anderson; Theresa Shek; Merone Roose-Girma; Nico Ghilardi; Menno van Lookeren Campagne
Journal:  J Exp Med       Date:  2009-12-28       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.